LIBX-A402
LIBX-A402 (Compound 15b) is a selective ACSL4inhibitor with an IC50 of 0.33 μM. LIBX-A402 significantly protects MDA-MB-231 and LUHMES cells from ferroptosis. LIBX-A402 can be used for cancer, ischemia-reperfusion injury and neurodegenerative diseases like Parkinson’s disease research[1].
Product Specifications
UNSPSC
12352005
Target
Ferroptosis
Related Pathways
Apoptosis
Field of Research
Cancer; Neurological Disease; Cardiovascular Disease
Smiles
O=C(C1=C(C2=CC(C)=CC=C2O1)NC(C)=O)C3=CC=CC=C3
Molecular Formula
C18H15NO3
Molecular Weight
293.32
References & Citations
[1]Mazhari Dorooee D, et al. LIBX-A401: A Novel Selective Inhibitor of Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode. Angew Chem Int Ed Engl. 2025 May;64 (19) :e202500518.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470977-500 1x 500 µL
TGF-beta (1D11.16.8), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400158-100 1x 100 µL
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680040-500 1x 500 µL
CD35 / CR1 (E11), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471037-500 1x 500 µL
CD44 Standard (DF1485), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880158-500 1x 500 µL
Cytokeratin 17 (E3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details